Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~* Participants with T2D treated with a Sulfonylurea (≥half the maximum recommended dose as per local label or maximum tolerated dose \[documented\]) as monotherapy or in combination with Metformin (≥1500 mg per day or maximum tolerated dose \[documented\]) each at a stable dose for at least 12 weeks without a dose adjustment before screening.~* Signed written informed consent.~Exclusion criteria:~* At the time of screening, age \<18 years or \< legal age of majority, whichever is greater.~* Body Mass Index (BMI) ≤20 or \>45 kilograms per meter square (kg/m\^2) at Screening.~* Hemoglobin A1c (HbA1c) \<7% or HbA1c \>10% via central lab test at screening.~* Fasting plasma glucose (FPG) \>15 mmol/L (270 mg/dL) measured by the central laboratory at screening (Visit 1), and confirmed (\>15 mmol/L \[270 mg/dL\]) by a repeat test before randomization.~* Women of childbearing potential with no effective contraceptive method.~* Treated with an antidiabetic pharmacological regimen other than a Sulfonylurea at a stable dose with or without Metformin within 12 weeks preceding the screening visit.~* Previous insulin use \>1 month (at any time, aside from treatment of gestational diabetes).~* History of prior gastric surgical procedure including gastric banding or inflammatory bowel disease within 3 years before the Screening Visit.~* History of diabetic ketoacidosis or nonketotic hyperosmolar coma within 12 weeks prior to the Screening Visit.~* History of severe hypoglycemia within 6 months prior to the Screening visit.~* Systolic blood pressure (SBP) \>180 millimeter per mercury (mmHg) or diastolic blood pressure (DBP) \>100 mmHg or history of hypertensive emergency.~* Aspartate aminotransferase and/or alanine aminotransferase: \>3 times the upper limit of the normal laboratory range (ULN).~* Total bilirubin: \>1.5 times ULN (except in case of Gilbert's syndrome).~* Use of systemic glucocorticoids (excluding topical or ophthalmic, application or inhaled forms) for more than 10 consecutive days within 90 days prior to the Screening Visit.~* Pregnancy, breastfeeding.~* Participants is unwilling to perform self-monitoring of blood glucose (SMBG), and complete the participant's diary as required per protocol.~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sotagliflozin 400 mg (Type: EXPERIMENTAL): Following a 2-week run-in phase, participants received two Sotagliflozin tablets of 200 mg, orally once daily, before the first meal of the day plus Metformin and Sulfonylurea as prescribed for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 79 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Following a 2-week run-in period, participants were randomized to matching placebo administered as 2 tablets, once daily, before the first meal of the day plus Metformin and Sulfonylurea as prescribed for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 79 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).